Circulation. 2002;106:1192-1194
Published online before print August 12, 2002, doi: 10.1161/01.CIR.0000031524.49139.29
Published online before print August 12, 2002, doi: 10.1161/01.CIR.0000031524.49139.29
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:1192.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease
From the Department of Metabolism, Endocrinology and Molecular Medicine (S.J., K.M., Y.N.), the Department of Cardiovascular Medicine (A.S.), and the Department of Geriatrics and Neurology (T.M.), Osaka City University Graduate School of Medicine, Osaka, Japan; and the Division of Cardiology, Mitsui Memorial Hospital (Y.I., K.H.), Tokyo, Japan.
Correspondence to Shuichi Jono, MD, Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. E-mail jono{at}med.osaka-cu.ac.jp
Background— Osteoprotegerin (OPG) is a secretory glycoprotein that belongs to the tumor necrosis factor receptor family. OPG-deficient mice develop severe osteoporosis and medial arterial calcification of the aorta and renal arteries. OPG immunoreactivity was demonstrated in the normal blood vessels and in early atherosclerotic lesions. A recent clinical study suggests that there is a significant correlation between elevated serum OPG levels and cardiovascular mortality. We examined whether serum OPG levels are associated with the progression of coronary artery disease (CAD).
Methods and Results— Serum OPG levels were examined in 201 patients who underwent coronary angiography because of stable chest pain. The number of diseased vessels was used to represent the severity of CAD. Serum OPG levels were measured by ELISA and were significantly greater in patients with significant stenosis of the coronary arteries than in those without stenosis. As the severity of CAD increased, there was a significant increase in serum OPG levels. Serum OPG levels were 0.94±0.34, 1.04±0.38, 1.19±0.38, and 1.44±0.54 ng/mL (medians 0.91, 0.99, 1.09, and 1.37) for the subjects with normal coronary arteries or luminal irregularities, 1-vessel disease, 2-vessel disease, and 3-vessel disease, respectively. Multivariate logistic regression analysis revealed that serum OPG levels were significantly associated with the presence of CAD [odds ratio, 5.2; 95% confidence interval, 1.7 to 16.0].
Conclusions— Our data show that serum OPG levels are associated with the presence and severity of CAD, suggesting that OPG may be involved in the progression of CAD.
Key Words: glycoproteins • coronary disease • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  G. Speer, B. Cs. Fekete, T. E. H. Othmane, T. Szabo, J. Egresits, E. Fodor, I. Kiss, A. G. Logan, J. Nemcsik, A. Szabo, et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients Nephrol. Dial. Transplant., May 13, 2008; (2008) gfn242v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lorz, A. Benito-Martin, A. Boucherot, A. C. Ucero, M. P. Rastaldi, A. Henger, S. Armelloni, B. Santamaria, C. C. Berthier, M. Kretzler, et al. The Death Ligand TRAIL in Diabetic Nephropathy J. Am. Soc. Nephrol., May 1, 2008; 19(5): 904 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-H. Gannage-Yared, C. Yaghi, B. Habre, S. Khalife, R. Noun, M. Germanos-Haddad, and V. Trak-Smayra Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study Eur. J. Endocrinol., March 1, 2008; 158(3): 353 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Omland, T. Ueland, A. M. Jansson, A. Persson, T. Karlsson, C. Smith, J. Herlitz, P. Aukrust, M. Hartford, and K. Caidahl Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 627 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Morony, Y. Tintut, Z. Zhang, R. C. Cattley, G. Van, D. Dwyer, M. Stolina, P. J. Kostenuik, and L. L. Demer Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr( / ) Mice Circulation, January 22, 2008; 117(3): 411 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Anand, E. Lim, D. Darko, P. Bassett, D. Hopkins, D. Lipkin, R. Corder, and A. Lahiri Determinants of Progression of Coronary Artery Calcification in Type 2 Diabetes: Role of Glycemic Control and Inflammatory/Vascular Calcification Markers J. Am. Coll. Cardiol., December 4, 2007; 50(23): 2218 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Mangan, A. V. Campenhout, C. Rush, and J. Golledge Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-{alpha} associated with induction of angiopoietin-2 Cardiovasc Res, December 1, 2007; 76(3): 494 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Orita, H. Yamamoto, N. Kohno, M. Sugihara, H. Honda, S. Kawamata, S. Mito, N. N. Soe, and M. Yoshizumi Role of Osteoprotegerin in Arterial Calcification: Development of New Animal Model Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2058 - 2064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Atteritano, H. Marini, L. Minutoli, F. Polito, A. Bitto, D. Altavilla, S. Mazzaferro, R. D'Anna, M. L. Cannata, A. Gaudio, et al. Effects of the Phytoestrogen Genistein on Some Predictors of Cardiovascular Risk in Osteopenic, Postmenopausal Women: A Two-Year Randomized, Double-Blind, Placebo-Controlled Study J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3068 - 3075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kiechl, G. Schett, J. Schwaiger, K. Seppi, P. Eder, G. Egger, P. Santer, A. Mayr, Q. Xu, and J. Willeit Soluble Receptor Activator of Nuclear Factor-{kappa}B Ligand and Risk for Cardiovascular Disease Circulation, July 24, 2007; 116(4): 385 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Zauli, F. Corallini, F. Bossi, F. Fischetti, P. Durigutto, C. Celeghini, F. Tedesco, and P. Secchiero Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo Blood, July 15, 2007; 110(2): 536 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Omland, M. H. Drazner, T. Ueland, M. Abedin, S. A. Murphy, P. Aukrust, and J. A. de Lemos Plasma Osteoprotegerin Levels in the General Population: Relation to Indices of Left Ventricular Structure and Function Hypertension, June 1, 2007; 49(6): 1392 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stompor, M. Krzanowski, B. Kusnierz-Cabala, M. Dubiel, M. Stompor, T. Grodzicki, and W. Sulowicz Pulse wave velocity and proteins regulating vascular calcification and bone mineralization in patients treated with peritoneal dialysis Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3605 - 3606. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Secchiero, F. Corallini, A. Pandolfi, A. Consoli, R. Candido, B. Fabris, C. Celeghini, S. Capitani, and G. Zauli An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction Am. J. Pathol., December 1, 2006; 169(6): 2236 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Bennett, M. Scatena, E. A. Kirk, M. Rattazzi, R. M. Varon, M. Averill, S. M. Schwartz, C. M. Giachelli, and M. E. Rosenfeld Osteoprotegerin Inactivation Accelerates Advanced Atherosclerotic Lesion Progression and Calcification in Older ApoE-/- Mice Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2117 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Shin, Y. G. Shin, and C. H. Chung Elevated Serum Osteoprotegerin Levels Are Associated With Vascular Endothelial Dysfunction in Type 2 Diabetes Diabetes Care, July 1, 2006; 29(7): 1664 - 1666. [Full Text] [PDF]
|
|
|
|
 |
|
 G.-d. Xiang, L. Xu, L.-s. Zhao, L. Yue, and J. Hou The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes, July 1, 2006; 55(7): 2126 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Anand, A. Lahiri, E. Lim, D. Hopkins, and R. Corder The Relationship Between Plasma Osteoprotegerin Levels and Coronary Artery Calcification in Uncomplicated Type 2 Diabetic Subjects J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1850 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Sandberg, A. Yndestad, E. Oie, C. Smith, T. Ueland, O. Ovchinnikova, A.-K. L. Robertson, F. Muller, A. G. Semb, H. Scholz, et al. Enhanced T-Cell Expression of RANK Ligand in Acute Coronary Syndrome: Possible Role in Plaque Destabilization Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 857 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Rasmussen, L. Tarnow, T. K. Hansen, H.-H. Parving, and A. Flyvbjerg Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients Eur. J. Endocrinol., January 1, 2006; 154(1): 75 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Galluzzi, S. Stagi, R. Salti, S. Toni, E. Piscitelli, G. Simonini, F. Falcini, and F. Chiarelli Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status Eur. J. Endocrinol., December 1, 2005; 153(6): 879 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rogers and R. Eastell Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Guang-da, S. Hui-ling, C. Zhi-song, and Z. Lin-shuang Changes in Plasma Concentrations of Osteoprotegerin before and after Levothyroxine Replacement Therapy in Hypothyroid Patients J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5765 - 5768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Avignon, A. Sultan, C. Piot, S. Elaerts, J. P. Cristol, and A. M. Dupuy Osteoprotegerin Is Associated With Silent Coronary Artery Disease in High-Risk but Asymptomatic Type 2 Diabetic Patients Diabetes Care, September 1, 2005; 28(9): 2176 - 2180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rattazzi, B. J. Bennett, F. Bea, E. A. Kirk, J. L. Ricks, M. Speer, S. M. Schwartz, C. M. Giachelli, and M. E. Rosenfeld Calcification of Advanced Atherosclerotic Lesions in the Innominate Arteries of ApoE-Deficient Mice: Potential Role of Chondrocyte-Like Cells Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1420 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Moran, M. McCann, M. Karan, P. Norman, N. Ketheesan, and J. Golledge Association of Osteoprotegerin With Human Abdominal Aortic Aneurysm Progression Circulation, June 14, 2005; 111(23): 3119 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ueland, A. Yndestad, E. Oie, G. Florholmen, B. Halvorsen, S. S. Froland, S. Simonsen, G. Christensen, L. Gullestad, and P. Aukrust Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure Circulation, May 17, 2005; 111(19): 2461 - 2468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Mosheimer, N. C. Kaneider, C. Feistritzer, A. M. Djanani, D. H. Sturn, J. R. Patsch, and C. J. Wiedermann Syndecan-1 Is Involved in Osteoprotegerin-Induced Chemotaxis in Human Peripheral Blood Monocytes J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2964 - 2971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Secchiero, F. Corallini, M. G. di Iasio, A. Gonelli, E. Barbarotto, and G. Zauli TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release Blood, May 1, 2005; 105(9): 3413 - 3419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nagasaki, M. Inaba, S. Jono, Y. Hiura, H. Tahara, K. Shirakawa, N. Onoda, T. Ishikawa, E. Ishimura, and Y. Nishizawa Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function Eur. J. Endocrinol., March 1, 2005; 152(3): 347 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ueland, R. Jemtland, K. Godang, J. Kjekshus, A. Hognestad, T. Omland, I. B. Squire, L. Gullestad, J. Bollerslev, K. Dickstein, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1970 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Demer and M. Abedin Skeleton key to vascular disease J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1977 - 1979. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Jorgensen, O. Joakimsen, G. K. Rosvold Berntsen, I. Heuch, and B. K. Jacobsen Low Bone Mineral Density Is Related to Echogenic Carotid Artery Plaques: A Population-based Study Am. J. Epidemiol., September 15, 2004; 160(6): 549 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification Endocr. Rev., August 1, 2004; 25(4): 629 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Soufi, M. Schoppet, A. M. Sattler, M. Herzum, B. Maisch, L. C. Hofbauer, and J. R. Schaefer Osteoprotegerin Gene Polymorphisms in Men with Coronary Artery Disease J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3764 - 3768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schoppet, N. Al-Fakhri, F. E. Franke, N. Katz, P. J. Barth, B. Maisch, K. T. Preissner, and L. C. Hofbauer Localization of Osteoprotegerin, Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, and Receptor Activator of Nuclear Factor-{kappa}B Ligand in Monckeberg's Sclerosis and Atherosclerosis J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4104 - 4112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Hofbauer and M. Schoppet Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases JAMA, July 28, 2004; 292(4): 490 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nitta, T. Akiba, K. Uchida, S. Otsubo, T. Takei, W. Yumura, T. Kabaya, and H. Nihei Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1886 - 1889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abedin, Y. Tintut, and L. L. Demer Vascular Calcification: Mechanisms and Clinical Ramifications Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1161 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Golledge, M. McCann, S. Mangan, A. Lam, and M. Karan Osteoprotegerin and Osteopontin Are Expressed at High Concentrations Within Symptomatic Carotid Atherosclerosis Stroke, July 1, 2004; 35(7): 1636 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Livshits, I Pantsulaia, S Trofimov, and E Kobyliansky Genetic influences on the circulating cytokines involved in osteoclastogenesis J. Med. Genet., June 1, 2004; 41(6): e76 - e76. [Full Text] [PDF]
|
|
|
|
|
|
S. Kiechl, G. Schett, G. Wenning, K. Redlich, M. Oberhollenzer, A. Mayr, P. Santer, J. Smolen, W. Poewe, and J. Willeit Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease Circulation, May 11, 2004; 109(18): 2175 - 2180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Hirose, H. Tomiyama, R. Okazaki, T. Arai, Y. Koji, G. Zaydun, S. Hori, and A. Yamashina Increased Pulse Wave Velocity Associated with Reduced Calcaneal Quantitative Osteo-sono Index: Possible Relationship Between Atherosclerosis and Osteopenia J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2573 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schoppet, J. R. Schaefer, L. C. Hofbauer, S. Jono, K. Mori, Y. Nishizawa, A. Shioi, T. Miki, Y. Ikari, and K. Hara Low Serum Levels of Soluble RANK Ligand Are Associated With the Presence of Coronary Artery Disease in Men * Response Circulation, March 25, 2003; 107 (11): e76 - e76. [Full Text] [PDF]
|
|